{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:29:58Z","timestamp":1778002198526,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":1363,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.14283\/jpad.2020.35","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:31:08Z","timestamp":1614238268000},"page":"48-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome"],"prefix":"10.1016","volume":"8","author":[{"given":"Michael S.","family":"Rafii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.L.","family":"Handen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.14283\/jpad.2020.35_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2990.1984.tb00351.x","article-title":"Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes","volume":"10","author":"Mann","year":"1984","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.14283\/jpad.2020.35_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","article-title":"Dementia in Down syndrome: unique insights for Alzheimer disease research","volume":"15","author":"Lott","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.14283\/jpad.2020.35_bib3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.mayocp.2013.04.024","article-title":"The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities","volume":"88","author":"Moran","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.14283\/jpad.2020.35_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trci.2016.02.004","article-title":"Dissociation of Down syndrome and Alzheimer's disease effects with imaging","volume":"2","author":"Matthews","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"10.14283\/jpad.2020.35_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jalz.2011.09.229","article-title":"Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B","volume":"8","author":"Handen","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.14283\/jpad.2020.35_bib6","first-page":"239","article-title":"The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome","volume":"14","author":"Rafii","year":"2015","journal-title":"Front Behav Neurosci"},{"issue":"5","key":"10.14283\/jpad.2020.35_bib7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000001212","article-title":"Age dependence of brain \u03b2-amyloid deposition in Down syndrome: An [18F]florbetaben PET study","volume":"84","author":"Jennings","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.14283\/jpad.2020.35_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with Down syndrome","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2020.35_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jalz.2015.05.013","article-title":"The effects of normal aging on amyloid-\u03b2 deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B","volume":"12","author":"Lao","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.14283\/jpad.2020.35_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jalz.2018.01.002","article-title":"Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition","volume":"14","author":"Cohen","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.14283\/jpad.2020.35_bib11","first-page":"1","article-title":"Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population","volume":"23","author":"Lao","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"10.14283\/jpad.2020.35_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2020.35_bib13","first-page":"111","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci. Transi. Med."},{"key":"10.14283\/jpad.2020.35_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2788.2006.00902.x","article-title":"Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology","volume":"51","author":"Margallo-Lana","year":"2007","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"10.14283\/jpad.2020.35_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-170390","volume":"60","author":"Rafii","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2020.35_bib16","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.neuroimage.2007.09.064","article-title":"Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events","volume":"39","author":"Haier","year":"2008","journal-title":"Neuroimage"},{"issue":"4","key":"10.14283\/jpad.2020.35_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneur.1995.00540280065020","article-title":"Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease","volume":"52","author":"Hof","year":"1995","journal-title":"Arch Neurol"},{"issue":"10","key":"10.14283\/jpad.2020.35_bib18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","article-title":"Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study","volume":"17","author":"Fortea","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.14283\/jpad.2020.35_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-018-0367-x","article-title":"Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome","volume":"10","author":"Strydom","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2020.35_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JAD-190322","article-title":"Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)","volume":"70","author":"Rafii","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2020.35_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1352\/1944-7558-125.2.97","article-title":"The Search for Biomarkers of Alzheimer's Disease in Down Syndrome","volume":"125","author":"Handen","year":"2020","journal-title":"Am J Intellect Dev Disabil"},{"key":"10.14283\/jpad.2020.35_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.trci.2018.10.006","article-title":"Alzheimer's disease in Down syndrome: An overlooked population for prevention trials","volume":"4","author":"Strydom","year":"2018","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:46:02Z","timestamp":1736469962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724004023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2274580724004023"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2020.35","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2020.35","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}